Mark Leick

Nov 9, 2023 | onclive.com | Mark Leick

November 9, 2023Mark Leick, MD, discusses the challenges and limitations associated with the use of CAR T-cell therapy across hematologic malignancies, highlighting how ongoing research may potentially ameliorate present unmet needs.

Nov 7, 2023 | onclive.com | Mark Leick

Mark Leick, MD, physician investigator, CCR Group C Monthly, Massachusetts General Research Institute, assistant professor, medicine, Harvard Medical School, assistant in medicine, Medicine-Hematology/Oncology, Massachusetts General Hospital, discusses the varying role of CAR T-cell therapy across various hematologic malignancies, elaborating on the cause of its effectiveness in these disease spaces.

Oct 11, 2023 | nature.com | Zachariah DeFilipp |Yi-Bin Chen |Areej El-Jawahri |Mark Leick

This is a preview of subscription content, access via your institution Access options Subscribe to this journalReceive 12 print issues and online access$259.00 per yearonly $21.58 per issueRent or buy this articlePrices vary by article typefrom$1.95to$39.95Prices may be subject to local taxes which are calculated during checkout ReferencesLuznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al.